MAN2A1 and neoplasm: Other cancer-driven mutations, including the EGFR mutation (L858R), genomic rearrangements (TMEM135-CCDC67 and MAN2A1-FER fusions), and the BRAF (V600E) driver mutation, have also been disrupted using CRISPR systems to control tumor growth 20, 21, 33.